Investment Thesis
Longeveron exhibits severe operational deterioration with 50% YoY revenue collapse and $4.8M operating losses on $398K revenue, indicating fundamental commercialization failure. Despite a fortress balance sheet ($15.8M cash, $143K debt), the company is burning $4.4M annually with only 3-4 years of runway and zero visible path to profitability or revenue recovery.
Strengths
- Strong balance sheet with $15.8M cash versus $143K long-term debt
- Excellent liquidity position with 3.88x current ratio providing operational buffer
- High gross margin of 66.3% suggests healthy product economics on limited revenue base
Risks
- Revenue collapsed 49.9% YoY indicating failed product commercialization or market rejection
- Operating cash burn of $4.4M annually with operating losses of $4.8M on minimal revenue
- Limited runway of 3-4 years at current burn despite strong balance sheet
- Negative ROE (-29.6%) and ROA (-22.3%) showing value destruction
- No meaningful capital expenditure despite pharmaceutical sector requirements for R&D
Key Metrics to Watch
- Quarterly revenue trend for stabilization or inflection
- Operating cash flow trajectory and sustainability of burn rate
- Cash balance depletion timeline and covenant compliance
- Clinical trial outcomes and regulatory approval status for pipeline products
- Gross margin sustainability on lower revenue base
Financial Metrics
Revenue
398.0K
Net Income
-4.7M
EPS (Diluted)
$-0.19
Free Cash Flow
-4.4M
Total Assets
21.2M
Cash
15.8M
Profitability Ratios
Gross Margin
66.3%
Operating Margin
-1,199.7%
Net Margin
-1,189.9%
ROE
-29.6%
ROA
-22.3%
FCF Margin
-1,098.0%
Balance Sheet & Liquidity
Current Ratio
3.88x
Quick Ratio
3.88x
Debt/Equity
0.01x
Debt/Assets
24.4%
Interest Coverage
-3.42x
Long-term Debt
143.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T09:40:56.810805 |
Data as of: 2026-03-31 |
Powered by Claude AI